The most comprehensive early detection framework in preventive medicine
Cancer is a group of diseases characterised by the uncontrolled growth and spread of abnormal cells. In 2026, approximately 2.1 million new cancer cases are projected in the US alone. The 5-year survival rate has reached 70% — demonstrating the transformative impact of early detection.
A complete clinical reference across all major body systems — the foundation of AETERNO's 200+ cancer type monitoring framework.
AETERNO's position is clear: true healing is integrative. The best outcomes combine the precision of biological medicine, the power of conventional oncology when necessary, and the restorative support of natural approaches. Early detection through AETERNO enables all three to work optimally.
The most revolutionary development in oncology in 30 years. Activates or enhances the immune system to recognise and destroy cancer cells.
Drugs designed to target specific genetic mutations or proteins that drive cancer growth — more precise than chemotherapy.
Systemic drugs that kill rapidly dividing cells. AETERNO's early detection maximises effectiveness by enabling Stage I-II intervention.
Light-activated drug produces reactive oxygen selectively toxic to cancer cells.
Many chemotherapy drugs are themselves derived from natural sources — refined over millions of years of evolution.
Most extensively researched natural cancer therapy in Europe. Standard integrative therapy in Germany, Switzerland, Austria — covered by insurance.
Cancer is, fundamentally, a disease of the genome. Approximately 5-10% of all cancers are hereditary. Identifying genetic predisposition enables enhanced surveillance, preventive interventions, and personalised AETERNO monitoring protocols.
| Syndrome | Gene(s) | Key Cancer Risks | Risk Level |
|---|---|---|---|
| Hereditary Breast & Ovarian Cancer (HBOC) | BRCA1, BRCA2 | Breast (50-72%), Ovarian (44%), Pancreatic, Prostate | HIGH |
| Lynch Syndrome (HNPCC) | MLH1, MSH2, MSH6, PMS2 | Colorectal (70-80%), Endometrial (40-60%), Ovarian (10-12%) | HIGH |
| Familial Adenomatous Polyposis (FAP) | APC | Colorectal near 100% by age 40, Duodenal, Thyroid | VERY HIGH |
| Li-Fraumeni Syndrome | TP53 | Lifetime cancer risk 90%+: Breast, Sarcomas, Brain, Leukemia | VERY HIGH |
| Cowden Syndrome | PTEN | Breast (25-50%), Thyroid (10%), Endometrial (28%) | HIGH |
| Von Hippel-Lindau (VHL) | VHL | Kidney (70%), Haemangioblastomas, Phaeochromocytoma | HIGH |
| Multiple Endocrine Neoplasia 1 (MEN1) | MEN1 | Parathyroid (95%), Pancreatic NET (30-70%), Pituitary (15-50%) | HIGH |
| Hereditary Diffuse Gastric Cancer | CDH1 | Gastric (56-83%), Breast lobular (42%). Prophylactic gastrectomy | HIGH |
| Peutz-Jeghers Syndrome | STK11 | Colorectal (40%), Pancreatic (11-36%), Breast (50%) | HIGH |
| Hereditary Melanoma (FAMMM) | CDKN2A | Melanoma (70%), Pancreatic (20-34%) | HIGH |
| Neurofibromatosis Type 1 (NF1) | NF1 | MPNST, Glioma, Breast, GIST, Leukemia | HIGH |
| Gorlin Syndrome (Basal Cell Naevus) | PTCH1 | Multiple BCC (often hundreds by age 20), Medulloblastoma | HIGH |
| Retinoblastoma (Hereditary) | RB1 | Bilateral retinoblastoma (90%), Osteosarcoma, Melanoma | VERY HIGH |
| MUTYH-Associated Polyposis (MAP) | MUTYH | Colorectal (80% lifetime), Duodenal, Ovarian | HIGH (biallelic) |
AETERNO's Oncology Signal module integrates thermal intelligence and blood biomarker analysis to detect early oncological signals across 13 cancer typologies — weeks or months before clinical symptoms appear.
No single biomarker is sufficient. The power of AETERNO's approach lies in the simultaneous analysis of multiple signal streams. The AI layer identifies pattern combinations that carry significantly higher predictive value than any individual marker.
A 52-year-old female, non-smoker, no family history. Standard annual check-up: all blood values within population reference ranges. No symptoms. Discharged as 'healthy' for another 12 months. What AETERNO detected — 8 weeks earlier.
8mm hypoechoic lesion confirmed on subsequent mammography. Core biopsy: Grade 1 invasive ductal carcinoma. Treatment: lumpectomy + radiotherapy. Without AETERNO: next scheduled mammography in 2 years — probable Stage II-III detection.
This framework is dedicated to the memory of those whose cancers were detected too late —
not because early signals did not exist, but because no infrastructure existed to detect and act upon them.
The biological signals of cancer precede clinical diagnosis. The mandate of modern preventive medicine
is to build the infrastructure that closes this gap.
AETERNO Life is that infrastructure.
AETERNO Life is designed and positioned as a health signal monitoring and early warning platform — explicitly not a medical diagnostic device. This positioning is deliberate, evidence-based, and clinically meaningful.
All AETERNO outputs use signal language: "Deviation from baseline detected" · "Pattern consistent with elevated inflammatory load" · "Clinical correlation recommended."
Never: "You have cancer" or "This is a diagnosis." Clinical diagnosis remains exclusively within the physician's domain.
10 European clinical institutions · 200 high-risk patients · 12 months
Prospective monitoring alongside standard clinical surveillance.
hello@aeternolife.ai · aeternolife.ai · aeterno-group.ai